GLP-1 Medications in India: Forms, Bioavailability & Administration (2026)

GLP-1 receptor agonists come in three administration formats: single-dose vials, multi-dose pre-filled pens, and oral tablets. Each has different bioavailability, dose flexibility, storage requirements, cost, and patient experience. This guide is the comprehensive reference for what's actually available in India in 2026 — including the branded products, the generic semaglutide options that launched after the March 2026 patent expiry, and the practical comparisons your doctor uses to choose between them.

The complete list of GLP-1 medications available in India (2026)

Drug	Molecule	Brand	Indication	Administration	Frequency
Ozempic	Semaglutide 0.25–2 mg	Novo Nordisk	T2D (off-label for weight)	Pre-filled pen	Once weekly
Wegovy (also: Poviztra co-marketed with Emcure)	Semaglutide 2.4 mg	Novo Nordisk	Chronic weight management	Pre-filled pen	Once weekly
Rybelsus	Semaglutide oral 3/7/14 mg	Novo Nordisk	T2D	Oral tablet	Once daily
Mounjaro	Tirzepatide 2.5–15 mg	Eli Lilly	T2D + chronic weight management	Single-dose vial / KwikPen	Once weekly
Yurpeak	Tirzepatide (Cipla co-marketed)	Cipla / Eli Lilly	T2D + chronic weight management	Pen	Once weekly
Indian generic semaglutide	Semaglutide (post-Mar 2026 patent expiry)	Cipla, Sun Pharma, Dr Reddy's, Lupin, Biocon and others	T2D / weight management	Pre-filled pen or vial	Once weekly
Liraglutide (Victoza)	Liraglutide 1.2–1.8 mg	Novo Nordisk	T2D	Pre-filled pen	Once daily
Liraglutide (Saxenda)	Liraglutide 3.0 mg	Novo Nordisk	Chronic weight management	Pre-filled pen	Once daily
Exenatide (Bydureon)	Exenatide ER	AstraZeneca	T2D	Pre-filled pen	Once weekly
Dulaglutide (Trulicity)	Dulaglutide 0.75–4.5 mg	Eli Lilly	T2D	Pre-filled pen	Once weekly

Some of these are widely available; some (Trulicity, Bydureon) are more limited in Indian distribution.

Administration formats explained

Single-dose vials

What it is: A small glass vial containing one weekly dose, drawn into a syringe at the time of injection.

Examples: Mounjaro (original launch format, March 2025).

Pros: Lower per-dose cost; precise dosing. Cons: Requires drawing the dose with a syringe (intimidating for many patients); harder to travel with; sharps disposal more complex.

When chosen: Patients comfortable with injection technique; some clinical settings; budget-sensitive patients.

Pre-filled multi-dose pens

What it is: A pen-shaped device containing multiple doses. You dial the dose, attach a new needle, and inject. The pen is refrigerated and used for ~4 – 6 weeks.

Examples: Wegovy, Ozempic, Mounjaro KwikPen, Yurpeak, Saxenda, Trulicity.

Pros: Easiest format for self-administration; doesn't require dose-drawing skill; needle is small (4–8 mm); easier to travel with (within reasonable temperature management). Cons: Slightly higher per-dose cost than vials; multi-week supply must be refrigerated between uses.

When chosen: Default for most patients in 2026. The KwikPen format (Mounjaro, August 2025) and the Wegovy pen are now the most-used formats in India.

Oral tablets

What it is: A daily pill taken on an empty stomach with a small amount of water.

Example: Rybelsus (oral semaglutide), 3/7/14 mg.

Pros: No injection; shelf-stable (no refrigeration); doesn't require sharps disposal. Cons: Very low bioavailability (~0.4 – 1%), so the maximum dose produces less weight loss than injectable semaglutide; strict daily ingestion protocol; not currently available at obesity-specific dosing (max 14 mg/day vs 2.4 mg/week subcutaneous, which has much higher effective bioavailability).

When chosen: Patients with strong needle aversion; patients in regions with cold-chain challenges; modest weight-loss goals or diabetes-only indication.

Bioavailability — why the format matters

Bioavailability = the percentage of an administered dose that reaches the bloodstream in active form.

Drug	Form	Bioavailability
Semaglutide	Subcutaneous (Ozempic / Wegovy / generic)	~89%
Semaglutide	Oral (Rybelsus) — with SNAC absorption enhancer	~0.4 – 1%
Tirzepatide	Subcutaneous (Mounjaro / Yurpeak)	~80%
Liraglutide	Subcutaneous (Victoza / Saxenda)	~55%
Exenatide	Subcutaneous (Byetta IR / Bydureon ER)	~65 – 75%
Dulaglutide	Subcutaneous (Trulicity)	~47 – 65%

The reason oral GLP-1 is so much lower: GLP-1 is a peptide, and peptides are normally destroyed by stomach acid and enzymes. Rybelsus tablets include a co-formulated sodium salcaprozate (SNAC) that creates a local pH change in the stomach, transiently protecting semaglutide long enough to absorb. Even so, only a fraction reaches the bloodstream.

This is why Rybelsus 14 mg/day (the maximum oral dose) produces less weight loss than Wegovy 2.4 mg/week (subcutaneous) — the absolute amount of active drug delivered is much smaller despite the dose number looking bigger.

Efficacy by drug, in head-to-head data

Average body weight loss over 68 – 72 weeks of treatment, at the indicated obesity / chronic-weight-management dose:

Drug	Dose	Mean weight loss	Trial
Tirzepatide (Mounjaro / Zepbound)	15 mg / week	~21 – 22%	SURMOUNT-1
Tirzepatide	10 mg / week	~19%	SURMOUNT-1
Tirzepatide	5 mg / week	~15%	SURMOUNT-1
Semaglutide (Wegovy)	2.4 mg / week	~14.9%	STEP-1
Semaglutide (Ozempic, off-label)	2 mg / week	~10 – 12%	STEP-2 sub-analysis
Liraglutide (Saxenda)	3.0 mg / day	~8 – 9%	SCALE
Semaglutide oral (Rybelsus)	14 mg / day	~5 – 8%	PIONEER
Exenatide ER	2 mg / week	~3 – 5%	DURATION trials
Dulaglutide	4.5 mg / week	~4 – 6%	AWARD-11 sub-analysis

This is why Wegovy and Mounjaro are the dominant prescriptions for weight management in 2026 — the magnitude of weight loss is meaningfully larger than older GLP-1 agonists.

Storage and stability

Drug	Refrigeration before first use	After first use	Heat tolerance
Wegovy / Ozempic pen	Yes (2 – 8°C)	Up to 56 days at room temp ≤30°C	Sensitive to heat
Mounjaro KwikPen	Yes (2 – 8°C)	Up to 21 days room temp ≤30°C	Sensitive
Mounjaro vials	Yes (2 – 8°C)	Use immediately after draw	Sensitive
Rybelsus	No (room temperature OK)	Same	Shelf-stable
Saxenda / Victoza	Yes (2 – 8°C)	Up to 30 days room temp	Sensitive

Indian climate matters. In summer months in Delhi, Chennai, Mumbai (temperatures regularly >35°C), refrigerated GLP-1 should be stored in the fridge throughout, even during the in-use period. Avoid car dashboards and direct sunlight.

Injection technique (subcutaneous formats)

The basics:

• Sites: abdomen (≥5 cm from belly button), front of thigh, back of upper arm
• Rotate sites each week to avoid lipohypertrophy
• Pinch the skin to lift subcutaneous tissue
• Insert needle at 90° (perpendicular to skin)
• Press the pen button fully; count to 6 before withdrawing
• Don't massage the site after
• Dispose of needle in a sharps container

Most pens use 4 – 8 mm needles. Pain is generally minimal — most patients report it feels "less than a vaccination."

Choosing the right form (the decision your doctor walks you through)

Choose a pen (Wegovy, Mounjaro KwikPen, Yurpeak) if:

• You're new to injections
• You value convenience
• You travel and want easier dose management
• You can manage cold storage

Choose a vial (Mounjaro vials) if:

• You're comfortable with syringes
• You want the lowest per-dose cost (rare scenario in 2026 given KwikPen pricing)

Choose oral (Rybelsus) if:

• You have strong needle aversion
• Cold storage is a problem
• You're managing T2D primarily, not obesity
• You can commit to the strict daily ingestion protocol (empty stomach, 30 min before food)

Choose generic semaglutide (post-March 2026) if:

• Cost is the primary constraint
• Your doctor is comfortable with the specific Indian manufacturer's track record
• You don't need a specific branded format

Cost summary (India, May 2026)

Drug	Form	Approx. monthly cost
Wegovy 2.4 mg (post Nov 2025 cut)	Pen	₹15,500 – ₹16,400
Ozempic 2 mg	Pen	₹15,000 – ₹18,000
Mounjaro KwikPen 15 mg	Pen	₹26,000 – ₹27,500
Mounjaro KwikPen 5 mg	Pen	₹15,000 – ₹17,500
Mounjaro vials 5 mg	Vial	₹17,500
Yurpeak (Cipla tirzepatide)	Pen	similar to Mounjaro
Generic Indian semaglutide	Pen / vial	₹3,000 – ₹6,000
Rybelsus 14 mg	Oral	₹9,000 – ₹13,000
Saxenda 3.0 mg	Pen	₹15,000 – ₹20,000

How Stride handles drug selection

Stride's prescribing clinicians select the GLP-1 drug + format based on:

• Your indication (weight management, T2D, or both)
• Your target weight loss
• Your tolerance for injections
• Your cost constraints
• Your storage situation (especially for tier-2 cities with intermittent refrigeration)
• Drug interactions and other medications

3-Month Early Edition: ₹9,999 (regular ₹23,999). Includes whichever GLP-1 your clinician selects, when clinically appropriate.

Frequently asked questions

Is generic semaglutide as effective as branded Wegovy? When manufactured by a quality-controlled licensed Indian pharma, yes — same molecule, same mechanism, same expected efficacy. Quality varies by manufacturer; your doctor will recommend a specific brand.

Can I switch between drugs? Yes, with medical supervision. Switching semaglutide → tirzepatide (or vice versa) is common when one isn't tolerated or isn't producing target loss.

Why is oral semaglutide (Rybelsus) so much less effective than injection? Bioavailability. Oral semaglutide reaches only 0.4 – 1% of the bloodstream vs ~89% for subcutaneous. Even at the maximum daily oral dose, the active drug delivered is much smaller.

Are there any GLP-1 pills equivalent to Wegovy? Not yet. Several oral GLP-1 / dual-agonist tablets are in late-stage trials (Novo's oral semaglutide 25 mg, orforglipron, retatrutide) but none are approved at obesity-level efficacy in oral form as of mid-2026.

Can I store my GLP-1 outside the fridge for a week? Most pens tolerate room temperature ≤30°C for 21 – 56 days after first use (check the specific drug's labelling). Sustained heat above 30°C degrades the peptide.

Do I need to refrigerate Mounjaro KwikPen? Yes before first use. After first use, room temperature ≤30°C up to 21 days. In Indian summer months, keep refrigerated when not in use.

Is needle pain a problem? Most patients report it's minimal — comparable to or less than a vaccination. Pens use very small 4 – 8 mm needles.

Can I split a dose if I run out? No — dosing is on a manufacturer-specified schedule. Splitting doses produces unpredictable blood levels and reduced efficacy.

Ready to start with the right drug for you?

Check your eligibility — Stride's clinicians select the right drug and format based on your individual profile.